Search NLS News

Nordic Nanovector has announced the appointment of Sandra Jonsson as Chief Operating Officer. Jonsson started on 10 January 2022 and took over from Marco Renoldi, who is retiring from the role but will remain as a consultant to the company. “I am very pleased that Sandra has agreed to join us at what is a […]

Oncorena receives a capital injection of 66 million SEK from one of the company’s principal shareholders together with two new investors. Under the terms of the agreement, Oncorena can receive an additional 94 million SEK in the future. The capital will primarily fund Oncorena’s first clinical study, a phase I/II study with orellanine in patients […]

AstraZeneca has closed a global development and commercialization agreement with Ionis Pharmaceuticals for eplontersen, formerly known as IONIS-TTR-LRX. The companies will jointly develop and commercialize eplontersen in the US, while AstraZeneca will develop and commercialize it in the rest of the world, except in Latin America. Financial considerations Under the terms of the agreement, the […]

Interim results from the second dose group in the company’s ongoing clinical phase I study SPAGOPIX-01 show that SpagoPix (SN132D) is well tolerated and provides clear contrast enhancement in MRI images of solid tumors in the breast, as well as in the pancreas and liver. Based on the results, the company has decided to continue […]

Nordic Life Science asked the newly formed company NordicRWE about the potential of Real-World Evidence in drug development and how we can better enable Nordic health data to be transformative and a frontrunner in this field. The amount of health-related data is rapidly increasing. At the same time, the healthcare sector is facing major challenges: […]

The Novo Nordisk Foundation Center for Stem Cell Medicine reNEW, will be established based on a new consortium of three institutions. The founding of the center is possible through an unprecedented grant of up to 300 million euro from the Novo Nordisk Foundation over a 10-year period. The center will be a collaboration between the […]

We would like to thank our readers, subscribers and collaboration partners for a fruitful 2021, and we wish you all a most wonderful holiday season! 2021 has been – yet another – challenging year and we have reported about both global and Nordic efforts to handle, treat and prevent COVID-19. But we have also seen […]

Gedea Biotech has received funding for a research project with the Centre for Translational Microbiome Research at Karolinska Institutet (KI), for its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). The project goal is to better understand the microbial etiology of bacterial vaginosis (BV) and factors associated with successful, antibiotic-free […]

The supplemental Biologics License Application (sBLA) for Ultomiris (ravulizumab-cwvz) in adults with generalised myasthenia gravis (gMG) has been accepted for Priority Review by the US Food and Drug Administration (FDA). The FDA set a Prescription Drug User Fee Act date during the second quarter of 2022, following use of a rare disease priority review voucher by Alexion, […]

AstraZeneca’s Saphnelo has been recommended for marketing authorization in the European Union (EU) as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite receiving standard therapy. If approved, Saphnelo would be the first new treatment for SLE in Europe in more than a decade, […]